Invivyd, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Invivyd is a clinical-stage biopharmaceutical company developing antibody therapies, initially targeting COVID-19. It has not generated revenue.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None reported | |||
| Research and development expense | $43.6 million | $37.1 million | $70.8 million | $129.2 million |
| Selling, general and administrative expense | $10.1 million | $14.6 million | $21.2 million | $23.3 million |
| Net loss | $50.2 million | $51.0 million | $85.5 million | $151.7 million |
| Net loss per share | $(0.46) | $(0.47) | $(0.78) | $(1.40) |
| Operating cash used | Not presented by quarter | $78.6 million | $116.4 million |
At June 30, cash and cash equivalents were $121.9 million and marketable securities were $176.5 million, totaling $298.4 million. Total assets were $315.4 million, liabilities $33.9 million, and stockholders’ equity $281.6 million. The filing reports no borrowings; lease liabilities totaled approximately $3.0 million. Gross margins are not applicable because the company had no revenue.
Changes versus the prior comparable periods
- Q2 operating expenses rose $2.1 million: R&D increased $6.5 million, including $31.5 million of direct VYD222 costs, while SG&A declined $4.5 million. Higher other income of $3.6 million helped reduce the net loss slightly year over year.
- For the first half, operating expenses fell $59.5 million and net loss narrowed $66.1 million. The main driver was substantially lower adintrevimab spending compared with 2022; VYD222 development and manufacturing costs increased.
- Six-month other income was $7.4 million, mainly interest and net accretion of marketable-security discounts. Operating cash use declined year over year. Investing cash inflows largely reflected maturities of securities, not operating earnings.
Outlook, developments, and risks
- Management said existing cash, cash equivalents and marketable securities were expected to fund operating and capital needs into the fourth quarter of 2024. The company expects continuing losses and may seek additional financing; its runway estimate depends on assumptions and could prove shorter.
- VYD222 Phase 1 dosing was completed in May. Initial results announced in June and July indicated tolerability at all three dose levels, no serious adverse events reported, and robust Day 7 neutralization of Omicron XBB.1.5. Further neutralization and pharmacokinetic analyses were ongoing.
- The company reported general alignment with the FDA on a potential EUA development pathway using immunobridging. In August 2023, it announced plans for the CANOPY pivotal trial: approximately 750 participants, with initial primary-endpoint data expected around year-end 2023. These are plans and expectations, not assurances of trial success or authorization.
- Post-quarter manufacturing commitments included $10.4 million for VYD222 resin (June) and $4.3 million for materials (July). The company also reported $8.9 million payable for VYD222 drug-substance batches, expected to be paid in the second half of 2023.
- Risks include clinical and regulatory uncertainty, changing SARS-CoV-2 variants and market conditions, reliance on contract manufacturers and other third parties, potential need for additional capital, and possible delays or disruption. The filing notes prior development delays related to the pandemic.
- A securities class action concerning statements about ADG20’s effectiveness against Omicron remained at an early stage; the company said it intended to defend itself and could not assess the outcome. Separately, the SEC notified the company on August 9, 2023 that it had concluded its investigation and did not intend to recommend action.
Important facts for investors to verify
- Whether CANOPY starts on schedule, enrolls as planned, and produces results supporting a potential EUA submission.
- VYD222’s durability and breadth of activity against circulating variants, and subsequent safety and pharmacokinetic findings.
- Actual cash burn, manufacturing and trial costs, and whether the stated runway into Q4 2024 remains achievable.
- Financing needs and potential dilution: 109.6 million common shares were outstanding at quarter-end; the filing also reports 6.8 million PHP warrants and 21.8 million outstanding stock options.
- Progress and potential financial impact of the securities litigation, and fulfillment of manufacturing commitments and vendor obligations.